Mind-Altering Drugs Media ArticlesExcerpts of Key Mind-Altering Drugs Media Articles in Major Media
Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
A group of Silicon Valley and Wall Street executives has raised $30 million to speed the development of a closely watched psychedelic-drug therapy. The Multidisciplinary Association for Psychedelic Studies, a nonprofit advocating for psychedelic research since the 1980s, is conducting its last phase of clinical trials to research the efficacy of using MDMA-assisted psychotherapy for post-traumatic stress disorder. PTSD afflicts about eight million adults a year. MDMA is more commonly known as the main component of Ecstasy. Armed with the new funding, MAPS is aiming to finish the trials and seek approval from the Food and Drug Administration to commercialize the MDMA-assisted psychotherapy as soon as 2022. In 2017, the FDA designated MDMA as a breakthrough therapy for PTSD, meaning it would expedite review of the drug. MAPS said a recent interim analysis of its Phase 3 clinical trials ... showed a very high likelihood the therapy will be effective for treating PTSD. In phase 2 clinical trials, individuals with post-traumatic stress disorder received psychotherapy, some with the psychedelic drug MDMA. More of those who received the drug no longer received a PTSD diagnosis in the months after treatment, compared with those who received a placebo. Business leaders said their donations came from a personal connection to mental-health conditions. Among them is billionaire Bob Parsons, founder of GoDaddy and ... a Marine Corps Vietnam War veteran, who said he has continued to battle PTSD.
Note: To read the entire article free of charge, see this webpage. Note that as big Pharma won't make big profits from these therapies, they are not funding any of the major studies, while the nonprofit MAPS has stepped in to make this happen. And not mentioned in this article is that the results of these studies has been dramatic, with over 2/3 of patients showing no signs of PTSD a year after treatment. For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
Older Americans suffer disproportionately from chronic pain and its attendant ailments, anxiety, depression and insomnia. In the search for relief, they consume more pharmaceutical drugs than perhaps any comparable cohort on this planet. Psychedelic therapies to treat mental health conditions offer a radical departure from current pharmaceutical models. The psychedelic therapy modalities currently under investigation combine a limited number of treatment sessions with a psychedelic substance, sandwiched between intensive pre- and post-treatment therapy sessions. The ideal, and realistic, outcome from this course of treatment is not mere symptom control, but durable remission. Indeed, these studies are finding that, in clinically significant numbers, recipients of a single course of psychedelic therapy report the experience to be life-changing, and enduring over time. The positive preliminary outcomes of clinical studies by MAPS using MDMA to treat PTSD, and Compass Pathways for psilocybin therapy for treatment-resistant depression, have convinced the FDA to grant them Breakthrough Therapy Designation. In the 1960s researchers were interested in seeing if psychedelic drug treatment could alleviate existential distress in terminal cancer patients. This line of research was picked up 35 years later by Dr. Charles Grob, whose 2011 pilot study of psilocybin treatment for terminal cancer patients found significant enduring reductions in anxiety and improvement in mood at a six-month follow up.
James “Whitey” Bulger terrorized Boston from the 1970s into the 1990s with a campaign of murder, extortion and drug trafficking. In 2013, Janet Uhlar was one of 12 jurors who found Bulger guilty in a massive racketeering case, including involvement in 11 murders. But now Uhlar says she regrets voting to convict Bulger on any of the murder charges. Her regret stems from a cache of more than 70 letters Bulger wrote to her from prison, some of which describe his unwitting participation in a secret CIA experiment with LSD. The agency dosed Bulger with the powerful hallucinogen more than 50 times when he was serving his first stretch in prison, in Atlanta. Uhlar has spoken publicly about her regret before but says her belief that the gangster was wrongly convicted on the murder charges was reinforced after reading a new book by Brown University professor Stephen Kinzer: “Poisoner in Chief: Sidney Gottlieb and the CIA Search for Mind Control.” Gottlieb’s secret program, known at MK-ULTRA, enlisted doctors and other subcontractors to administer LSD in large doses to prisoners, addicts and others unlikely to complain. Uhlar reviewed the 1977 hearings by the U.S. Senate Committee on Intelligence, which was looking into MK-ULTRA, and found testimony where CIA director Stansfield Turner acknowledged evidence showing that the agency had been searching for a drug that could prepare someone for “debilitating an individual or even killing another person.”
Can the mind-blowing effects of psychedelics help heal our traumas? The scientific community [says] it's an increasingly hopeful thumbs up. Despite the fact that psychedelics are illegal, the last decade has seen an explosion of research, with results so intriguing that governments are greenlighting studies around the world. Scientists are busily exploring the role of hallucinogens on treatment-resistant depression, post traumatic stress disorder, cancer-related anxiety, addictions, and even anorexia. During the '40s and early '50s tens of thousands of patients took LSD and other psychotropics to study their effects on cancer anxiety, alcoholism, opioid use disorder, depression, and ... PTSD. Researchers began to see psychedelics as possible "new tools for shortening psychotherapy." In the 1950s UK psychiatrist Dr. Humphry Osmond began giving LSD to treatment-resistent alcoholics: 40% to 45% of those who took LSD were still sober after a year. [Then] in 1970, President Richard Nixon ... classified hallucinogenics as Schedule I drugs -- the most restrictive category. [Fast forward to today and] MAPS is in the final phase of a gold-standard study administering MDMA [Ecstasy] to 300 people with severe PTSD. Results of the second phase showed 68% of the people no longer met the criteria for PTSD at a 12-month follow-up; before the study they had suffered from treatment-resistant PTSD for an average of 17.8 years. The results are so positive that in January the FDA declared MDMA-assisted psychotherapy for PTSD a "Breakthrough Therapy." Perhaps one day soon a trip to the therapist will include a trip into your mind, and hopefully, a quicker path to healing.
Note: The full article at the link above gives a concise, yet thorough survey of the use of psychedelics for healing and growth over the years. For more along these lines, see concise summaries of deeply revealing news articles on the powerful healing potentials of some psychedelics from reliable major media sources.
At this week’s World Economic Forum (WEF) in Davos, Switzerland, where the cannabis industry enjoyed a whole pavilion of its own, the biggest takeaway was where cannabis is headed in terms of human health. Rick Doblin, executive director of MAPS, the Multidisciplinary Association for Psychedelic Studies ... has delivered a TED talk on the future of psychedelic-assisted psychotherapy. And at Davos there was strong interest in the plant-based psychedelic molecules Doblin works with, [pharmacist Saul] Kaye said. “If you look at cannabis as an entryway into the market for botanical-based medicines, you can look at mushrooms, psilocybin,” said Kaye. “You can look at ibogaine, ayahuasca, which are new medicinal models that are breaking out in the world based on botanical medicine that has been illegal for the last 100 years. “Cannabis has elevated access to all kinds of botanical-based medicines, which ultimately can change mental health, physical health; and it’s a fascinating area that we can ... elevate the conversation around.” Other topics at the cannabis forum ... merited an “elevated” conversation of their own. A speaker from StemCell United, for example, addressed the fast expansion of CBD companies in Asia, building on what Kaye termed “a global de-stigmaization” across the Asian markets. The result, he said, has been to begin changing the traditional impression of cannabis from “This is illicit, this is a drug,” to, “This a research drug that is much safer than alcohol and tobacco.”
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
For most, psychedelic drugs conjure up images of the 1960's, hippies tripping out on LSD or magic mushrooms. But ... these powerful, mind-altering substances are now being studied seriously by scientists inside some of the country's foremost medical research centers. They're being used to treat depression, anxiety and addiction. The early results are impressive, as are the experiences of the studies' volunteers who go on a six-hour, sometimes terrifying, but often life-changing psychedelic journey. For nearly two decades now, [scientist Roland Griffiths] and his colleague Matthew Johnson have been giving what they call "heroic doses" of psilocybin to more than 350 volunteers, many struggling with addiction, depression and anxiety. Carine McLaughlin was a smoker for 46 years and said she tried everything to quit before being given psilocybin at Johns Hopkins last year. That was more than a year ago; she says she hasn't smoked since. The study she took part in is still ongoing, but in an earlier, small study of just 15 long-term smokers, 80% had quit six months after taking psilocybin. That's double the rate of any over-the-counter smoking cessation product. Jon Kostakopoulos was drinking a staggering 20 cocktails a night ... when he decided to enroll in another psilocybin trial at New York University. During one psilocybin session, he was flooded with powerful feelings and images from his past. He took psilocybin in 2016. He says he hasn't had a drink since.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
At 74, the venture capitalist George Sarlo might not have seemed an obvious candidate for an ayahuasca experience. Mr. Sarlo’s close friend, a doctor, told him about ayahuasca, a psychedelic brew made from the Banisteriopsis caapi vine, native to the Amazon. Used for centuries in sacred healing traditions throughout Central and South America, ayahuasca is now gaining popularity around the world. [It] is mostly illegal in the United States. Notably, ayahuasca’s increasing popularity knows no age limits: many of those now showing interest are squarely in Mr. Sarlo’s own demographic. Mr. Sarlo himself was initially skeptical. Taking ayahuasca would entail a potentially distressing night of hallucinations, and excretions of all kind, especially vomiting. But he still decided to head to Yelapa, a small village in Mexico, and swallow down the bitter brew. Mr. Sarlo said that afterward, something shifted. “It changed my life completely.” He realized that his life had been “absolutely full of miracles,” he said. As Michael Pollan put it, “psychedelics might be wasted on the young.” Mr. Pollan, the author of the recent best seller “How To Change Your Mind,” a history of psychedelics and a chronicle of his own experiences trying them, said ... he was surprised by the number of people he encountered when writing his book in their 70s and 80s expressing interest in trying psychedelics. Though perhaps he shouldn’t have been: as he himself has written, one of the reasons to come to psychedelics later in life is to tangle with one’s own mortality.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
A new biography by Stephen Kinzer ... "Poisoner in Chief: Sidney Gottlieb and the CIA Search for Mind Control" ... traces the life and career of Gottlieb. [He was] the brains behind ... MK-ULTRA, the notorious research endeavor that employed mind-altering drugs, including LSD. In 1952, Gottlieb led a team of scientists to a safehouse in Munich ... where prisoners of war were pumped full of drugs, interrogated and then allowed to die. [Back in the U.S.,] Gottlieb worked with a sadistic narcotics officer in opening a “national security whorehouse” to dose unwitting victims being serviced by prostitutes on the C.I.A. payroll. Drugging johns was easy, but when Gottlieb started dosing unwitting government colleagues the research hit turbulence. Frank Olson, an Army scientist working with MK-ULTRA who had been given LSD without his knowledge, jumped, or was possibly pushed, out of a hotel room window in New York in 1953. [Olson's story is] covered most recently in [the] docudrama “Wormwood.” His death has overshadowed the “expendables.” We just don’t know most of their names since Gottlieb destroyed the records. Some of the details in the book, like the coercion of African-American prisoners to participate in C.I.A. experiments, are astounding. [MK-ULTRA] should be remembered for what it was: a vehicle for abominable experiments that often targeted the most vulnerable — drug users, prisoners and psychiatric patients, who were deprived of meaningful informed consent. Kinzer’s book is also a good reminder that there is rarely legal accountability for the C.I.A.’s misdeeds.
Note: Explore concise excerpts from the astounding declassified CIA documents on MK-ULTRA. They reveal a very successful program to create Manchurian Candidates or spies who don't know they are spies. The Times' title of this article implies that the CIA is no longer into mind control. If you think that is true, think again. For more along these lines, see concise summaries of deeply revealing news articles on mind control from reliable major media sources. Then explore the excellent, reliable resources provided in our Mind Control Information Center.
During the early period of the Cold War, the CIA became convinced that communists had discovered a drug or technique that would allow them to control human minds. In response, the CIA began its own secret program, called MK-ULTRA, to search for a mind control drug that could be weaponized against enemies. MK-ULTRA, which operated from the 1950s until the early '60s, was created and run by a chemist named Sidney Gottlieb. Some of Gottlieb's experiments were covertly funded at universities and research centers ... while others were conducted in American prisons and in detention centers in Japan, Germany and the Philippines. Many of his unwitting subjects endured psychological torture ranging from electroshock to high doses of LSD. In the early 1950s, he arranged for the CIA to pay $240,000 to buy the world's entire supply of LSD. He brought this to the United States, and he began spreading it around to hospitals, clinics, prisons and other institutions, asking them, through bogus foundations, to carry out research projects and find out what LSD was, how people reacted to it and how it might be able to be used as a tool for mind control. MK-ULTRA, was essentially a continuation of work that began in Japanese and Nazi concentration camps. Not only was it roughly based on those experiments, but the CIA actually hired the vivisectionists and the torturers who had worked in Japan and in Nazi concentration camps to come and explain what they had found out so that we could build on their research.
Johns Hopkins Medicine announced the launch of the Center for Psychedelic and Consciousness Research, to study compounds like LSD and psilocybin for a range of mental health problems, including anorexia, addiction and depression. The center is the first of its kind in the country, established with $17 million in commitments from wealthy private donors and a foundation. The centers at Johns Hopkins and Imperial College give “psychedelic medicine,” as some call it, a long-sought foothold in the scientific establishment. Since the early 2000s, several scientists have been exploring the potential of psychedelics and other recreational drugs for psychiatric problems, and their early reports have been tantalizing. The emergence of depression treatment with the anesthetic and club drug ketamine and related compounds, which cause out-of-body sensations, also has piqued interest in mind-altering agents as aids to therapy. The ... funding will help clarify which drugs help which patients. Roland Griffiths, a neuroscientist at Johns Hopkins who will direct the new center ... said the new funds will cover six full-time faculty, five postdoctoral scientists and the costs of running trials. Among the first of those trials are a test of psilocybin for anorexia nervosa and of psilocybin for psychological distress and cognitive impairment in early Alzheimer’s disease. “The one that’s crying out to be done is for opiate-use disorder, and we also plan to look at that,” Dr. Griffiths said.
Note: Learn about the fascinating man who is bankrolling a significant portion of this new center in this New York Times article. For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
MDMA is the main ingredient in club drugs ecstasy or molly. But [Lori] Tipton wasn't taking pills sold on the street to get high at a party. She was trying to treat her post-traumatic stress disorder, with the help of licensed therapists. Two specially-trained psychotherapists ... sat next to Tipton as she recalled some of her deepest traumas, like discovering her mother's body after a murder-suicide. "I was able to find such empathy for myself. I realized how much I was thinking this was my fault," she says. The synthetic psychoactive chemical MDMA is emerging as a promising — if unconventional — treatment for PTSD. Scientists are testing how pharmaceutical-grade MDMA can be used in combination with psychotherapy to help patients who have a severe form of PTSD that has not responded to other treatments. It's not yet available as a treatment for PTSD outside of clinical trials, but the success of early trials has proponents hopeful that the therapy could be available to more people in coming years. They're aiming for approval by the The Food and Drug Administration, which granted breakthrough therapy status to MDMA-assisted psychotherapy in 2017. After the Phase 2 trials of MDMA-assisted treatments concluded in 2017, researchers found 54% of the patients who took MDMA had improved to the point that they no longer fit the diagnosis for PTSD (compared to 23% in the control group). A year later, the number who no longer had PTSD had risen to 68% percent.
Hallucination-inducing drugs like magic mushrooms could be about to break big pharma’s stranglehold on the hugely lucrative market for antidepressants, according to the head of the world’s first centre for psychedelic research. Antidepressant prescriptions have doubled in England in a decade with around seven million adults taking the drugs, and the global market is predicted to be worth $15.9bn (Ł12.5bn) by 2023. At Imperial College London, Dr Robin Carhart-Harris is leading one of the first trials to test how therapy using psilocybin mushrooms, which are currently banned in the UK, compares to leading antidepressants. While he won’t prejudge the results of the study, he says participants describe a cathartic emotional “release” with psilocybin therapy – the polar opposite of antidepressants, which patients complain leave their emotions, whether positive or negative, “blunted”. It is the first of many studies planned under the banner of the new Centre for Psychedelic Research at London’s Imperial College. Dr James Rucker is another of those researching the potential benefits of psychedelics ... at King’s College London. The King’s team are launching two trials, one looking at whether psilocybin therapy can help people whose depression is resistant to treatment with conventional antidepressants. He says it was “possible” the drug could be licensed in five years.
Carlos Plazola locked himself in a bedroom while his cousin stood guard. For five hours, he tripped on magic mushrooms. He ingested 5 grams - a heady amount that connoisseurs call the “heroic dose.” It was Plazola’s first time using the mushrooms, which contain the naturally occurring hallucinogen psilocybin. He started having epiphanies, one right after the other, like lightning bolts. “I was making connections that I had never made in terms of my understanding of what we are, what the cosmos are, why we’re here, where we’re going,” Plazola said. That mushroom trip last October by Plazola, the well-connected onetime chief of staff of a former Oakland City Council president, helped make Oakland the first city in California and the second in the nation to effectively decriminalize magic mushrooms. In May, Denver became the first city in the nation to decriminalize psilocybin mushrooms. In Oakland ... the City Council on June 4 approved its ordinance unanimously, with little pushback. Oakland even went a step further by decriminalizing not just mushrooms but also a range of other psychoactive plants and compounds including peyote, iboga and ayahuasca. The measure ... does not actually legalize natural psychedelics, which remain illegal under state and federal law. Instead, it declares the arrest and investigation of adults for using, possessing, growing or distributing plant-based hallucinogens to be among the lowest priorities for local police and restricts the use of city funds to go after users.
Note: Forbes recently published an excellent article clearing up the hype about some aspects of this sensitive subject. For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
UCSF psychiatrist Brian Anderson is studying an experimental therapy to help long-term AIDS survivors ... who are feeling sad and demoralized. In a clinic outfitted with a comfortable couch, soft lighting, throw pillows and blankets, the participants of his study are given psilocybin, the hallucinogenic compound found in magic mushrooms. The results were compelling enough that he’s planning a second study. Anderson’s work is part of a resurgence in psychedelic study that has been ... fueling grassroots efforts around the country to decriminalize use of certain psychedelic drugs. Statewide measures are being discussed in California and Oregon. The decriminalization efforts are focused on natural psychedelics — mushrooms, along with herbs, cacti and other plants from which hallucinogenic compounds can be extracted. Though several studies in the first half of the 20th century had shown promise in using psychedelics for treatment of mental health and neurological disorders, the drugs were broadly maligned in the 1960s and ’70s. More recently, microdosing — the practice taking small, carefully controlled amounts of a psychedelic — has taken off among Silicon Valley techies and university students who believe it boosts productivity and creativity. Almost all studies at the moment rely on private donations for funding. Studies are still limited, but they’re happening at universities around the country. At Johns Hopkins, Johnson and his colleagues reported about an 80% success rate in using psilocybin to help people quit smoking in one small study. Research out of UCLA has found that psilocybin may help cancer patients with depression and anxiety.
Note: For more along these lines, see concise summaries of deeply revealing news articles on studies of psychedelics from reliable major media sources.
You’ve probably heard about microdosing, the “productivity hack” popular among Silicon Valley engineers and business leaders. Microdosers take regular small doses of LSD or magic mushrooms. At these doses, they don’t experience mind-bending, hallucinatory trips, but they say they get a jolt in creativity and focus that can elevate work performance, help relationships, and generally improve a stressful and demanding daily life. Late last year, the first placebo-controlled microdose trial was published. The study concluded that microdoses of LSD appreciably altered subjects’ sense of time, allowing them to more accurately reproduce lapsed spans of time. Does a microdose change brain function? There’s a myriad of ways to test this, but [Devin] Terhune looked specifically at the way the subjects perceive time. When shown a blue dot on a screen for a specific length of time, the subjects were asked to recreate that length of time by pressing a key. Typically, with longer time intervals, people underrepresent time (i.e. hold the key down for a shorter period of time than reality). In the study, those who received microdoses held the key longer, better representing the actual time interval. Does this mean microdosing makes you smarter? Terhune and his co-authors were cautious in overinterpreting their finding. For one, it’s not clear that perceiving time more accurately is preferable. The brain seems to favor underrepresenting time for reasons that are unclear. The finding does show that microdoses changed brain function.
Psychedelic medicine is having a moment. Just weeks after the U.S. Food and Drug Administration approved Johnson & Johnson’s ketamine-like nasal spray for depression, a group of European technology investors ... got together for the largest-ever private financing round for a psychedelic medicine biotech company, ATAI. Psychedelic medicine involves research and investigations into mind-altering substances to treat mental illnesses including addiction, depression and post-traumatic stress disorder. After recreational use of psychedelics became popular in the 1960s, the U.S. government classified most of them “drugs of abuse” with no real medical value. However, recent clinical studies show mounting evidence that some psychedelics can help patients with certain mental illnesses, either in combination with traditional therapies or in cases where nothing else has worked. Now health and technology investors are paying attention. German company ATAI Life Sciences announced on Tuesday that it has raised more than $40 million in new financing. The round valued the company at $240 million, according to a person familiar, making it both the biggest round and the most valuable company in the young space. ATAI is currently funding clinical trials for what it refers to as “formerly stigmatized compounds,” including psilocybin, the active compound in psychedelic mushrooms, and arketamine, a different variant of ketamine from the one Johnson & Johnson researched, as potential treatments for depression.
Note: Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.
The US Food and Drug Administration approved Janssen Pharmaceuticals Inc.'s esketamine on Tuesday for treatment-resistant depression; the drug is the chemical cousin of ketamine, the powerful anesthetic that has been used illegally as the club drug Special K. It will be sold as Spravato. It's for patients who have tried at least two other medications without success, and it should be taken with an oral antidepressant. "There has been a longstanding need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition," Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products at the FDA's Center for Drug Evaluation and Research, said. Spravato is a nasal spray administered by an approved health care provider in a doctor's office or a medical clinic. It may also be self-administered but only under the supervision of a care provider and cannot be taken home. Depending on the severity of the patient's depression, it is given either once a week or once every other week. The drug is rapidly acting, so it starts working faster than other antidepressants, according to Janssen. It works by restoring brain cells in patients with treatment-resistant depression. Currently available treatments for major depression are ineffective in 30% to 40% of patients. The drug was designated as a breakthrough therapy in 2013, a status intended to "expedite the development and review of drugs for serious or life-threatening conditions," the FDA said at the time.
CBD, the non-psychoactive compound found in cannabis, hemp and hops, has been getting a lot of attention from the media recently. On the other hand, THC, the psychoactive compound in cannabis that makes people feel “high” or “stoned,” is often overlooked (and sometimes even looked down on) when discussing marijuana’s medical potential. However, a new study ... published on the Scientific Reports journal on Tuesday, revealed that THC exhibited the “strongest correlation with therapeutic relief, compared to the more socially acceptable chemical found in cannabis, CBD (cannabinol).” Cannabinoid content, and especially THC content, came out as the main factor for optimizing symptom relief, when tested for a wide variety of health conditions. [Study co-author Jacob Miguel] Vigil explained the results derived from the observation of real-time data from Releaf App, which he qualified as “the largest database of its kind in our country.” Using the app, patients reported the results and effects of their actual cannabis use. The researchers discovered cannabis is more effective for the treatment of mental symptoms like agitation, irritability, anxiety, depression, excessive appetite, insomnia, loss of appetite, nausea, gastrointestinal pain, stress and tremors, than it is in the treatment of physical ailments. Despite the conventional wisdom ... that only CBD has medical benefits while THC merely makes one high, our results suggest that THC may be more important than CBD in generating therapeutic benefits.
MDMA, the principal ingredient in the party drug ecstasy, is about to give a lifeline to some of the worst sufferers of post-traumatic stress disorder (PTSD) in Israel. The U.S. could be just years behind in launching similar clinical treatments using the substance. Israel’s Ministry of Health has approved the use of MDMA, a psychoactive drug, for use on dozens of patients. While the drug is still on the country’s law books as dangerous for recreational use, it is now being administered as treatment for compassionate use. In compassionate cases the drug will be made available to patients outside of clinical trials if they have not responded sufficiently to other medications or treatments. MDMA makes people feel euphoric, a sensation that made its use synonymous with rave culture and EDM (Electronic Dance Music), because it floods the body with serotonin. Serotonin is produced by nerve cells. When levels are low it can lead to depression and disrupt other physiological processes. The launching of the new Israeli initiative is a direct result of groundbreaking research in the U.S. The Middle Eastern nation approved the program after sending a representative to the California-based Multidisciplinary Association for Psychedelic Studies (MAPS) for training. MDMA has been illegal in the U.S. since 1985 but the findings of clinical trials, ongoing with Food and Drug Administration (FDA) approval since 2001, have shown that the drug enhances the treatment of PTSD in a clinical setting.
Note: Read also a CBC article titled "How psychedelic drugs are changing lives and transforming psychiatry." For more along these lines, see concise summaries of deeply revealing mind altering drugs news articles from reliable major media sources.
MDMA, the active ingredient of ecstasy pills, makes people more inclined to cooperate on tasks and quicker to rebuild trust, according to researchers investigating its use in treating psychological disorders. Scans reveal it increases activity in parts of the brain linked to empathy and social behaviour that helps interpret other people’s beliefs and intentions, researchers from King’s College London said. This could make it a useful addition to psychotherapy sessions and the drug is currently undergoing medical trials to assess its use in supporting treatment of post-traumatic stress disorder (PTSD). “Understanding the brain activity underlying social behaviour could help identify what goes wrong in psychiatric conditions,” said Professor Mitul Mehta from the King’s Institute of Psychiatry, Psychology & Neuroscience (IoPPN). While it is possible that making users more helpful and collaborative could lead to them being exploited, Professor Mehta and his team found the drug did not make users gullible. During the study ... participants on MDMA were less likely to cheat their partners than those on the placebo. Where they had previously been cheated ... subjects on MDMA were as likely to act selfishly as those on a placebo, however they were quicker to trust these partners again after a run of cooperation. This was backed up with patterns of brain activity.
Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.